William Blair & Company’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.5M | Sell |
31,546
-1,878
| -6% | -$99.1K | ﹤0.01% | 823 |
|
|
2025
Q4 | $1.75M | Sell |
33,424
-315
| -0.9% | -$18.9K | ﹤0.01% | 782 |
|
|
2025
Q3 | $2.19M | Sell |
33,739
-1,391
| -4% | -$79.9K | 0.01% | 711 |
|
|
2025
Q2 | $1.71M | Sell |
35,130
-33,087
| -49% | -$1.28M | ﹤0.01% | 758 |
|
|
2025
Q1 | $2.32M | Sell |
68,217
-46,183
| -40% | -$1.96M | 0.01% | 679 |
|
|
2024
Q4 | $4.5M | Sell |
114,400
-7,509
| -6% | -$355K | 0.01% | 523 |
|
|
2024
Q3 | $5.73M | Sell |
121,909
-13,060
| -10% | -$663K | 0.02% | 467 |
|
|
2024
Q2 | $7.29M | Sell |
134,969
-12,921
| -9% | -$747K | 0.02% | 393 |
|
|
2024
Q1 | $10.1M | Buy |
147,890
+11,190
| +8% | +$801K | 0.03% | 329 |
|
|
2023
Q4 | $8.56M | Buy |
136,700
+3,814
| +3% | +$211K | 0.03% | 350 |
|
|
2023
Q3 | $6.03M | Buy |
132,886
+1
| +0% | +$52 | 0.02% | 394 |
|
|
2023
Q2 | $7.46M | Buy |
132,885
+3,670
| +3% | +$208K | 0.03% | 364 |
|
|
2023
Q1 | $5.84M | Buy |
129,215
+49,622
| +62% | +$2.41M | 0.02% | 408 |
|
|
2022
Q4 | $3.24M | Sell |
79,593
-3,098
| -4% | -$164K | 0.01% | 524 |
|
|
2022
Q3 | $5.4M | Buy |
82,691
+2,259
| +3% | +$164K | 0.02% | 391 |
|
|
2022
Q2 | $4.89M | Sell |
80,432
-33,892
| -30% | -$1.99M | 0.02% | 422 |
|
|
2022
Q1 | $7.18M | Buy |
114,324
+22,302
| +24% | +$1.4M | 0.03% | 383 |
|
|
2021
Q4 | $6.97M | Sell |
92,022
-2,799
| -3% | -$245K | 0.02% | 416 |
|
|
2021
Q3 | $10.6M | Buy |
94,821
+7,192
| +8% | +$903K | 0.04% | 318 |
|
|
2021
Q2 | $14.2M | Buy |
87,629
+7,157
| +9% | +$870K | 0.05% | 267 |
|
|
2021
Q1 | $9.81M | Buy |
80,472
+9,637
| +14% | +$1.46M | 0.04% | 320 |
|
|
2020
Q4 | $10.8M | Buy |
70,835
+1,179
| +2% | +$139K | 0.04% | 287 |
|
|
2020
Q3 | $5.83M | Buy |
69,656
+3,413
| +5% | +$303K | 0.02% | 367 |
|
|
2020
Q2 | $4.87M | Sell |
66,243
-910
| -1% | -$53.2K | 0.02% | 386 |
|
|
2020
Q1 | $2.85M | Sell |
67,153
-3,425
| -5% | -$177K | 0.02% | 450 |
|
|
2019
Q4 | $4.3M | Buy |
70,578
+10,928
| +18% | +$597K | 0.02% | 424 |
|
|
2019
Q3 | $2.44M | Sell |
59,650
-1,900
| -3% | -$90.8K | 0.01% | 528 |
|
|
2019
Q2 | $2.9M | Buy |
61,550
+46,315
| +304% | +$1.85M | 0.02% | 482 |
|
|
2019
Q1 | $544K | Buy |
15,235
+100
| +0.7% | +$3.46K | ﹤0.01% | 939 |
|
|
2018
Q4 | $432K | Buy |
15,135
+1,200
| +9% | +$41.7K | ﹤0.01% | 962 |
|
|
2018
Q3 | $618K | Sell |
13,935
-1,763
| -11% | -$92.3K | ﹤0.01% | 887 |
|
|
2018
Q2 | $922K | Buy |
15,698
+198
| +1% | +$11.3K | 0.01% | 752 |
|
|
2018
Q1 | $709K | Buy |
+15,500
| New | +$640K | 0.01% | 805 |
|
|
2017
Q4 | – | Sell |
-15,500
| Closed | -$277K | – | 1379 |
|
|
2017
Q3 | $277K | Buy |
+15,500
| New | +$281K | ﹤0.01% | 1138 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
William Blair & Company's CRSP Position: Q1 2026 in Review
William Blair & Company reduced its CRISPR Therapeutics (CRSP) stake by 5.6% in Q1 2026, selling an estimated $99.1K and leaving 31,546 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #823.
William Blair & Company first reported a position in CRSP in Q3 2017 and has held it in 34 quarters since. The position peaked at $14.2M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- William Blair & Company held 31,546 shares of CRISPR Therapeutics worth $1.5M as of Q1 2026.
- William Blair & Company sold 1,878 CRISPR Therapeutics shares in Q1 2026, an estimated $99.1K.
- CRISPR Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #823 holding.
- William Blair & Company first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 34 quarters since.
- William Blair & Company's CRISPR Therapeutics position peaked at $14.2M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.